Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs-Reference-Cited by-同舟云学术

Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs

Published:2018-03-01 Issue:3 Volume:22 Page:239-245
ISSN:1027-3719
Container-title:The International Journal of Tuberculosis and Lung Disease
language:en
Short-container-title:int j tuberc lung dis

Author:

Van Deun A.¹,Decroo T.²,Piubello A.³,de Jong B. C.⁴,Lynen L.²,Rieder H. L.⁵

Affiliation:

1. Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium, International Union Against Tuberculosis and Lung Disease, Paris, France

2. Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp

3. International Union Against Tuberculosis and Lung Disease, Paris, France, Damien Foundation, Brussels, Belgium

4. Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

5. Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland

Publisher

International Union Against Tuberculosis and Lung Disease

Subject

Infectious Diseases,Pulmonary and Respiratory Medicine

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A machine-learning based model for automated recommendation of individualized treatment of rifampicin-resistant tuberculosis;PLOS ONE;2024-09-06

2. Mitigating treatment failure of pulmonary pre-extensively drug-resistant tuberculosis: The role of new and repurposed drugs;Journal of Microbiology, Immunology and Infection;2024-08

3. Safety of high-dose amikacin in the first week of all-oral rifampicin-resistant tuberculosis treatment for the prevention of acquired resistance (STAKE): protocol for a single-arm clinical trial;BMJ Open;2024-07

4. Relapse after treatment with standardized all-oral short regimens for rifampicin-resistant tuberculosis (RR-TB): A systematic review and meta-analysis;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2024-05

5. Treatment Outcomes of Fluoroquinolone- Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid - Authors’ Reply;Tuberculosis and Respiratory Diseases;2024-04-01